ClinicalTrials.gg
CompletedNCT04736173ARC-10Updated Oct 19, 2026

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

A Phase 2 interventional study of Domvanalimab and Zimberelimab in Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer and Squamous Non Small Cell Lung Cancer, sponsored by Arcus Biosciences, Inc.. Completed at 38 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Arcus Biosciences, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, 2 of them phase 3. zimberelimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 10
169 · median 152
Started
2021
with 2 others
Phase 2
4 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
Arcus Biosciences, Inc.

Among the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About zimberelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing zimberelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Nonsquamous Non Small Cell Lung Cancer
  • Squamous Non Small Cell Lung Cancer
  • Lung Cancer

Keywords

  • Domvanalimab
  • Zimberelimab
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed, treatment naïve, locally advanced or (stage IIIB IV per AJCC version 8), squamous or non-squamous NSCLC with documented high PD L1 expression (TC ≥ 50%) as determined by the VENTANA SP263 IHC assay, as assessed by central laboratories).
  • (ECOG) performance status score of 0 or 1
  • Must have at least 1 per v1.1
  • Adequate organ and marrow function
  • If a participant has brain or meningeal metastases, the participant must meet the following criteria:

    1. Have no evidence of progression by neurologic symptoms or signs for at least 4 weeks prior to the first dose.
    2. Participants with previously treated may participate provided they have stable central nervous system (CNS) disease for at least 4 weeks prior to enrollment. Stable CNS disease is defined as resolution of all neurologic symptoms to baseline, having no evidence of new or enlarging brain metastases, and not requiring use of for CNS disease for at least 14 days prior to the start of study treatment. Participants who have had brain metastases resected or have received whole brain radiotherapy ending at least 4 weeks (or stereotactic radiotherapy ending at least 2 weeks) prior to initiation of study treatment are permitted.
    3. Carcinomatous meningitis is excluded regardless of clinical stability.

Key Exclusion Criteria:

  • Presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved by local health authority and available
  • Use of any against infectious diseases within 28 days of first dose
  • Any active disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or drugs), except for vitiligo or resolved childhood asthma/atopy.
  • Prior active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
  • Prior treatment with any , anti-PD-L1 or any other antibody targeting an immune checkpoint.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Active comparator
    Arm A - Study Part 1 (Platinum-based Chemotherapy)

    Participants will receive carboplatin, pemetrexed, and paclitaxel by intravenous (IV) infusion.

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed

  • Experimental
    Arm B - Study Part 1 (Zimberelimab Monotherapy)

    Participants will receive zimberelimab monotherapy by IV infusion.

    Drug: Zimberelimab

  • Experimental
    Arm C - Study Part 1 (Domvanalimab + Zimberelimab Combination Therapy)

    Participants will receive zimberelimab in combination with AB154 by IV infusion.

    Drug: Domvanalimab · Drug: Zimberelimab

  • Experimental
    Arm D - Study Part 2 (Domvanalimab + Zimberelimab Combination Therapy)

    Participants will receive domvanalimab in combination with zimberelimab by IV infusion.

    Drug: Domvanalimab · Drug: Zimberelimab

  • Active comparator
    Arm E - Study Part 2 (Pembrolizumab)

    Participants will receive pembrolizumab by IV infusion.

    Drug: Pembrolizumab

Interventions

  • Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

    Also known as: AB154

  • Zimberelimab is a fully human anti-PD-1 monoclonal antibody

    Also known as: AB122

  • Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

  • Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

  • Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

  • Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Time frame: From randomization until death from any cause (up to 7 years)

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: From randomization until death from any cause (up to 7 years)

  2. Confirmed Overall Response Rate (ORR)

    Time frame: From randomization until death from any cause (up to 7 years)

  3. Number of Participants With treatment-emergent adverse events

    Time frame: From randomization until death from any cause (up to 7 years)

07

Study locations

38 sites
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    Blacksburg, Virginia 24060, United States
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Johor Bahru, Malaysia
  • Research Site
    Kuala Lumpur, Malaysia
  • Research Site
    Kuantan, Malaysia
  • Research Site
    Kuching, Malaysia
  • Research Site
    Pulau Pinang, Malaysia
  • Research Site
    Putrajaya, Malaysia
  • Research Site
    Davao City, Philippines
  • Research Site
    Manila, Philippines
  • Research Site
    George, South Africa
  • Research Site
    Johannesburg, South Africa
  • Research Site
    Pretoria, South Africa
  • Research Site
    Daegu, South Korea
  • Research Site
    Incheon, South Korea
  • Research Site
    Jinju, South Korea
  • Research Site
    Seoul, South Korea
  • Research Site
    Suwon, South Korea
  • Research Site
    Taichung, Taiwan
  • Research Site
    Bangkok, Thailand
  • Research Site
    Changwat Sara Buri, Thailand
  • Research Site
    Chanthaburi, Thailand
  • Research Site
    Chiang Mai, Thailand
  • Research Site
    Khon Kaen, Thailand
  • Research Site
    Lampang, Thailand
  • Research Site
    Nakhon Nayok, Thailand
  • Research Site
    Nakhon Ratchasima, Thailand
  • Research Site
    Phitsanulok, Thailand
  • Research Site
    Songkhla, Thailand
  • Research Site
    Ubon Ratchathani, Thailand
  • Research Site
    Adana, Turkey (Türkiye)
  • Research Site
    Ankara, Turkey (Türkiye)
  • Research Site
    Edirne, Turkey (Türkiye)
  • Research Site
    Istanbul, Turkey (Türkiye)
  • Research Site
    Kocaeli, Turkey (Türkiye)
  • Research Site
    Hanoi, Vietnam
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2026, 67 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 67 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion May 2027 → Sep 2026 and completion May 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 3, 2021
StartActual
Feb 8, 2021
Primary completionActual
Sep 17, 2026was May 2027
CompletionActual
Sep 17, 2026was May 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Sites
1 site removed
Show 1 removed
  • Research Site · Huế, Vietnam
Oct 5, 2026
Primary completion
May 2027→Sep 17, 2026 (actual)
Oct 19, 2026
Study completion
May 2027→Sep 17, 2026 (actual)
Oct 19, 2026
Show all 2 updates
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Primary completion May 2027→Sep 17, 2026 (now actual)
    Study completion May 2027→Sep 17, 2026 (now actual)
  2. Oct 5, 2026
    1 site removed
    Show 1 removed
    • Research Site · Huế, Vietnam

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04736173
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Feb 8, 2021
Primary completion
Sep 17, 2026
Completion
Sep 17, 2026
Last update
Oct 19, 2026

Study contacts

Medical Director
study director · Arcus Biosciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Domvanalimab · Zimberelimab

Start the discussion